RxDoctor Payments Data

John Guzek, MD

Internal Medicine · Scranton, PANPI 1861460545

Payments from drug & device makers

$7,039in general payments, 2019–2025

Across 410 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$921
  • AstraZeneca$653
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$361
  • Lundbeck LLC$343
  • Novartis$326
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,039 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$54,472
Medicare patients
184
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$113,869
OzempicSemaglutide107$98,627
JardianceEmpagliflozin36$49,735
FarxigaDapagliflozin Propanediol65$47,561
EliquisApixaban51$41,395
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$21,895
TrulicityDulaglutide14$20,327
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,173
WegovySemaglutide11$13,829
Repatha SureclickEvolocumab18$9,820
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,180
EntrestoSacubitril/Valsartan11$7,904
Varenicline Tartrate29$5,405
Rosuvastatin Calcium206$2,866
Atorvastatin Calcium116$1,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$227$134,196109 claims
Novo NordiskOzempic, Wegovy$1,078$112,456118 claims
AstraZenecaFarxiga, Breztri Aerosphere$653$69,45693 claims
Boehringer IngelheimJardiance$69$49,73536 claims
PfizerEliquis$174$41,39551 claims
GSKTrelegy Ellipta, Anoro Ellipta$103$26,35439 claims
NovartisEntresto$326$7,90411 claims
AbbVieSynthroid$921$60113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →